Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Biotechnology

Healthcare
$1.40 +3.16%

+$0.05 today

Market cap
$60.08M
Beta
1.91
P/E (TTM)
-0.8
EPS (TTM)
-$2.00
52W Low $1.15High $3.56

Volume 0.37M

Average 0.60M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$63.66M

FY 2025 · Annual

Investing Cash Flow

$66.10M

FY 2025 · Annual

Financing Cash Flow

-$749,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.24M)(31.17M)(60.39M)(80.56M)(77.91M)
Depreciation & Amortization37K364K536K1.01M919K
Deferred Income Tax00(3.61M)00
Stock-Based Compensation497K2.19M11.62M14.29M14.72M
Change in Working Capital328K(1.53M)8.14M2.44M(2.43M)
Accounts Receivables00000
Inventory00000
Accounts Payables798K(245K)3.61M(3.59M)1.54M
Other Working Capital(470K)(1.29M)4.53M6.02M(3.96M)
Other Non-Cash Items1.4M33K1.06M(2.85M)1.03M
Operating Cash Flow(13.98M)(30.12M)(42.64M)(65.67M)(63.67M)
Capital Expenditures(238K)(2.17M)(1.29M)(2.77M)(1.67M)
Acquisitions (Net)00000
Purchases of Investments0(150.18M)(56.53M)(202.93M)(81.73M)
Sales of Investments010.67M108.53M153.92M149.5M
Other Investing Activities00000
Investing Cash Flow(238K)(141.68M)50.72M(51.77M)66.1M
Debt Repayment00000
Common Stock Issued0104.46M(257K)70M1K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1K(2.75M)(1.3M)51.03M(750K)
Financing Cash Flow112.22M101.71M(1.55M)121.03M(749K)
Effect of Forex Changes00000
Net Change in Cash98M(70.08M)6.52M3.59M1.69M
Free Cash Flow(14.22M)(32.28M)(43.93M)(68.44M)(65.33M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$77.9M
+ D&A$919.0K
+ Stock-Based Comp$14.7M
+ Deferred Tax$0
- Working Capital-$2.4M
+ Other Non-Cash$1.0M
= Operating Cash Flow-$63.7M
- Capex-$1.7M
= Free Cash Flow-$65.3M

Analysis

FY2025 free cash flow is -$65.3M. FCF conversion is 83.9% of net income. Operating cash flow was -$63.7M, with capex of -$1.7M. The largest bridge item is Stock-Based Comp at $14.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
8-KCurrent reportNov 6, 2026
4Statement of changes in beneficial ownershipOct 26, 2026
4Statement of changes in beneficial ownershipOct 7, 2026
4Statement of changes in beneficial ownershipSep 2, 2026

Does ACRV generate free cash flow?

Acrivon Therapeutics, Inc. Common Stock (ACRV) generated -$65.33M of free cash flow in fiscal 2025.

How much operating cash flow does ACRV produce?

Operating cash flow was -$63.66M, before capital expenditures of $1.67M.